

# Abstract Submission/Guidelines

Dear Colleagues,

On behalf of the International Mesothelioma Interest Group (iMig) and the French Cooperative Thoracic Intergroup (IFCT), it is a great pleasure and an honour to extend you a warm invitation to join us for the 16th International Conference of the international Mesothelioma interest group (iMig 2023) to be held on June 26th – 28th 2023 in Lille, France.

Building on the experience and the success of previous great meetings since the founding of iMig in Paris in 1991 our multidisciplinary conference will bring together delegates from around the world and feature the most up-to-date research on diverse topics of interest.

Through workshops, plenary sessions, oral abstracts, poster sessions, and other events, this meeting will offer you plenty of networking opportunities with leading scientists and researchers, and also with patients and their associations. The resulting stimulating ideas will help to establish research collaborations and to fund projects.

We are very proud and excited to host the iMig Conference in France again at the beginning of summer 2023 in Lille, a modern city with friendly and beautiful traditions.

It is an exciting time for mesothelioma research and management, and we hope you will be able to join us for this outstanding scientific event.

We look forward to seeing you at iMig 2023!

## KEY DATES

16th International Conference of the International Mesothelioma Interest Group

**Dates:** 26, 27 and 28 June 2023

**Venue:** Lille Grand Palais

**Website:** <https://imig2023.org/>

—

**Abstract submission opening day:** 2 January 2023

**Abstract submission closing day:** ~~6 February 2023~~ -> 20 February 2023

**Scientific committee decision:** 20 March 2023

## INSTRUCTIONS FOR ABSTRACTS

Please submit a fully original work, in English

### IMPORTANT REMINDER:

**"Any selected and registered speaker who does not present their oral presentation or poster, except in the event of force majeure, will not be able to present a paper the following year".**

—

### Instructions to authors for abstract writing:

1. The title of the abstract must not exceed 25 words.
2. The abstract must not exceed 500 words i.e. approximately 3500 characters (including spaces).
3. Tables and figures: count for 100 words each. The relevance of using table/figures will be taken into account. Image: 2 maximum, count for 100 words each. The real interest of the use of image will be noted. **DOWNLOAD A PDF DOCUMENT ONLY, NOT EXCEEDING 500Kb/Image/Table**
4. Abstracts must be structured as follow: Objectives, Method, Results, Conclusions.  
*Warning: evaluation of the abstracts by the reading committee is anonymous, therefore the body of the text must not contain any reference to the team or center (eliminatory element).*
5. The following information must be provided for the contact person: surname, first name, position, department, postal address, phone number, and e-mail address.  
Authors and their affiliations must be clearly stated. The first author is the one who will present the work in an oral presentation if the poster is selected. An author can only appear once as first author (in the same category).
6. In order to comply with the regulations, abstracts must mention only the INNs of the medicines and not their trade names.
7. Please declare a "conflict of interest" if the work has been funded by a company or if you (or any of the abstracts co-authors) receive personal remuneration from a company whose product is used in the work submitted for this paper.
8. The abstract, whatever the mode of presentation (oral or written), may be published in full in the final digital program of the 2023 Conference.
9. Submission of ongoing clinical trials is allowed.
10. During the submission of your abstract, you must indicate if you are submitting for a written or oral communication or if you wish the scientific committee to decide.



**CATEGORIES OPEN FOR SUBMISSION**

**Theme 1:** Biomarkers, Genetics/Bioinformatics

**Theme 2:** Pathology and improvement of (Pleural) Mesothelioma diagnosis

**Theme 3:** Imaging (including staging issues, innovations, AI...)

**Theme 4:** Patient experience: supportive care, symptoms management

**Theme 5:** Surgery and multimodal treatment

**Theme 6:** Radiation oncology (within multimodal treatment or not)

**Theme 7:** Epidemiology and asbestos control, including health promotion /advocacy / prevention session

**Theme 8:** Immunology and Immunotherapy: including combination of treatments; gene and cell therapies (CAR T...) and other intra-pleural treatments

**Theme 9:** Mesothelioma biology (including pre-clinical models) and novel targets

**Theme 10:** Clinical Trials (including trials in progress)

**Theme 11:** Peritoneal mesothelioma

**Theme 12:** Nursing and Allied Health

The best abstracts will be awarded during the Young Investigators session on 27 June 2023.

**SCORING SYSTEM**

Evaluation of the abstracts is carried out by a committee of experts.

The decisions of the committee will be communicated on 20 March 2023 by email.

Each abstract will be reviewed and scored as follows:

1. Clinical importance and scientific methodology.
2. Quality and relevance of the potential iconography used: table, figures, diagram, photo, video, internet link.
3. The committee will then decide whether the abstract is to be presented as an ORAL PRESENTATION or a DISPLAYED POSTER.
4. The final marks will be determined and the committee will rule on any ties.

**D-DAY**

If you are selected for an oral or poster presentation, you will receive instructions the 20th of March 2023 by email.

You shall participate on a voluntary basis like all members of the Scientific Committee.

You will speak alone - First author.

The presence and registration of the first author (or a substitute if necessary) is mandatory.

We count on your participation and thank you in advance. Congress information available at [imig2023.org](http://imig2023.org)

